Vascular Normalizing Agents Differentially Modulate Tumor Cells, T Cells and Dendritic Cells in vitro
ISEF · 2020 Biomedical and Health Sciences
Overview
Tertiary lymphoid structures (TLS) are lymph node-like structures that form at sites of inflammation, and their presence in cancer patients is predictive of a better clinical outcome. One significant obstacle to TLS formation is reduced immune cell infiltration into the tumor microenvironment (TME) as a result of an aberrant vasculature within the TME. Recent studies have shown that vascular normalizing (VN) agents may override this defect, leading to improved tissue perfusion and increased immune cell entry into the TME. However, the effects of VN agents on immune cell and tumor cell phenotype/function remain understudied. It was hypothesized that treating T cells and DCs with VN agents would induce a pro-inflammatory phenotype, while treating tumor cells would reduce their immunosuppressive phenotype and promote production of chemokines that foster TLS formation. To test this, a BPR melanoma cell line and primary murine T cells and DCs were treated overnight with VN agents. The next day, samples of treated and untreated cells of each cell type were harvested for analyses to measure transcript levels of target genes as well as relative frequencies of cell surface markers. Treatment of tumor cells lead to increased TLS production of TLS-promoting factors. While Aduro and Bevacizumab were strongly and weakly immunostimulatory for T cells respectively, Dasatinib was predominantly immunosuppressive. Meanwhile, VN agents decreased MHC and co-stimulatory molecule expression on DCs but increased TLS promoting chemokine transcript levels. Overall, VN agents have differential effects on immune and tumor cell phenotype. Future experiments will analyze immunomodulatory effects within the TME in vivo to further determine optimal immunotherapy designs in the cancer setting.
Competition history
- ISEF 2020
Resources
Related projects
ISEF · 2023
TNF Ligand Promotes Angiogenesis in Triple Negative Breast Cancer Through Activation of Inflammatory Regulatory Networks
ISEF · 2020
Targeted Delivery of Immune Agonists for Antitumoral Response of the Tumor Microenvironment
ISEF · 2014
VEGF-3 Antibody Functionalized Gold Nanoshells for Near Infrared Photothermal Ablation of Lymphatic Endothelial Cells
ISEF · 2025
VISTA Inhibitor CA170 Synergizes With KRAS Vaccine in Lung Cancer in a Single-Cell RNA Sequencing Analysis
Closest projects by meaning, across every fair and year in the corpus.
Source: Regeneron International Science and Engineering Fair